ArticleTranslational lung cancer research2026

Neo-DIANA: descriptive results of a prematurely terminated phase II trial of neoadjuvant atezolizumab, chemotherapy and bevacizumab in resectable EGFR-mutated NSCLC.

Ana Collazo-Lorduy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.